Record Revenue Achievement
Cooper Companies achieved all-time record revenues of $3.9 billion in fiscal 2024, with both CooperVision and CooperSurgical reporting record revenues.
Strong Performance in CooperVision
CooperVision reported quarterly revenues of $676 million, up 9% or 8% organically, driven by strength in silicone hydrogel dailies and multifocals.
Fertility Segment Growth
CooperSurgical's fertility segment reported quarterly revenues of $139 million, up 15% or 13% organically, with significant market share gains.
Non-GAAP Earnings Growth
Non-GAAP earnings per share grew 19% to $1.04, reflecting strong earnings growth and margin improvements.
Advances in Myopia Management
MiSight fitting activity remained strong with a 24% growth, and CooperVision expects around 40% growth in fiscal 2025.
Commitment to Price Increases and Efficiency
Price increases and efficiency gains led to a slight improvement in gross margins to 66.9%, with operating income up 16.2%.